Eculizumab
- Generic Name
- Eculizumab
- Brand Names
- Soliris, Epysqli, Bekemv
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 219685-50-4
- Unique Ingredient Identifier
- A3ULP0F556
- Background
Eculizumab is a monoclonal antibody that targets complement protein C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.
...
- Indication
Eculizumab is indicated in the US to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy, and neuromyelitis optica spectrum disorder (NMOSD). It is also indicated in EU to treat PNH in both adult and pediatric patients.
- Associated Conditions
- Generalized Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorders, Paroxysmal Nocturnal Haemoglobinuria (PNH), Thrombotic Microangiopathies
- Associated Therapies
- -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
- Conditions
- Interventions
- First Posted Date
- 2012-12-27
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Russian Academy of Medical Sciences
- Target Recruit Count
- 57
- Registration Number
- NCT01756508
- Locations
- 🇷🇺
Russian Scientfic Center of Surgery, Moscow, Russian Federation
An Open Label Study of the Effects of Eculizumab in CD59 Deficiency
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2012-04-18
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 5
- Registration Number
- NCT01579838
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01567085
A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant
- Conditions
- Interventions
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Schroppel, Bernd, M.D.
- Target Recruit Count
- 8
- Registration Number
- NCT01403389
- Locations
- 🇺🇸
Mount Sinai Recanati/Miller Transplantation Institute, New York, New York, United States
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT01399593
Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Sanjay Kulkarni
- Target Recruit Count
- 16
- Registration Number
- NCT01327573
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Therapy of Chronic Cold Agglutinin Disease With Eculizumab
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- University Hospital, Essen
- Target Recruit Count
- 13
- Registration Number
- NCT01303952
- Locations
- 🇩🇪
Department of Hematology, University Hospital Essen, Essen, Germany
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
- Conditions
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Registration Number
- NCT01275287
- Locations
- 🇺🇸
UNC Kidney Center, Chapel Hill, North Carolina, United States
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 6
- Registration Number
- NCT01221181
- Locations
- 🇺🇸
Columbia University Medical Center, Nephrology Clinical Research Center, New York, New York, United States
🇺🇸Columbia University Medical Center, Glomerular Center, New York, New York, United States
E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT01194804
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.